ZSCAN4: A Potential Drug Target and Biomarker (G201516)

Target Name: ZSCAN4

NCBI ID: G201516

ZSCAN4

ZSCAN4: A Potential Drug Target and Biomarker

ZSCAN4, also known as ZSCAN4 variant 2, is a protein that is expressed in various tissues and cells throughout the body. It is a scaffold protein that is involved in the formation of tight junctions, which are a type of cell-cell barrier that helps to maintain tissue structure and function. ZSCAN4 is also known for its role in cell signaling, as it has been shown to play a role in the regulation of cell growth, differentiation, and survival.

The discovery of ZSCAN4 and its functions have generated a lot of interest in the field of drug development, as a potential drug target and biomarker. ZSCAN4 has been shown to be involved in a number of diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, ZSCAN4 has emerged as a promising drug target for a variety of diseases, and research is ongoing to determine its potential utility as a drug or biomarker.

One of the key challenges in the development of ZSCAN4 as a drug target is its expression and stability. ZSCAN4 is a protein that is expressed in many different tissues and cells throughout the body, which can make it difficult to target. Additionally, ZSCAN4 is a scaffold protein, which means that it is involved in the formation of tight junctions, which can make it difficult to target and manipulate.

However, researchers have been able to overcome these challenges and have shown that ZSCAN4 can be a valuable drug target. Studies have shown that ZSCAN4 can be targeted with small molecules, such as inhibitors or modulators, which can inhibit its activity and disrupt its formation of tight junctions. These small molecules have been shown to have a variety of effects on ZSCAN4, including the inhibition of cancer cell growth and the regulation of cell signaling.

In addition to its potential as a drug target, ZSCAN4 has also been shown to be a potential biomarker. Its expression is regulated in response to various environmental and biological factors, which can make it a useful marker for tracking changes in cellular behavior and health. For example, ZSCAN4 has been shown to be regulated by factors such as cell density, growth factors, and stress, which can make it a useful marker for tracking the effects of drugs on cancer cell growth and differentiation.

Another potential benefit of ZSCAN4 as a drug target is its potential to treat a variety of diseases and conditions. Its role in cell signaling and cell-cell barrier formation makes it a potential target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, ZSCAN4 has been shown to be involved in the regulation of cell survival and growth in cancer cells, which makes it a potential target for cancer treatments.

In conclusion, ZSCAN4 is a protein that has the potential to be a valuable drug target and biomarker. Its expression and stability make it a challenging target, but its role in cell signaling and cell-cell barrier formation makes it a promising target for the development of new drugs and therapies. Further research is needed to fully understand the potential utility of ZSCAN4 as a drug target and biomarker, and to develop effective treatments for a variety of diseases.

Protein Name: Zinc Finger And SCAN Domain Containing 4

Functions: Embryonic stem (ES) cell-specific transcription factor required to regulate ES cell pluripotency. Binds telomeres and plays a key role in genomic stability in ES cells by regulating telomere elongation. Acts as an activator of spontaneous telomere sister chromatid exchange (T-SCE) and telomere elongation in undifferentiated ES cells (By similarity)

The "ZSCAN4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZSCAN4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets